EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	999	(546/118,514/303).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/21 06:40
L2	176	l1 and aminopyridine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/21 06:40
L3	1	l2 and inflammator	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/21 06:41
L4	40	l2 and n-oxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/09/21 06:41

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:35:34 ON 21 SEP 2007

=> file reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.42 | 0.42

FILE 'REGISTRY' ENTERED AT 06:36:50 ON 21 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573204.str





chain nodes :
10 11 18 19 20 21 22 23 24 27
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
8-10 9-19 10-11 10-20 10-27 11-12 11-21 11-22 13-23 15-24 16-18
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-7 4-9 7-8 8-9 10-27 16-18
exact bonds :
8-10 9-19 10-11 10-20 11-12 11-21 11-22 13-23 15-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

G1:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 06:37:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:37:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 167 TO ITERATE

100.0% PROCESSED 167 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L3 27 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.52

FILE 'CAPLUS' ENTERED AT 06:37:19 ON 21 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Sep 2007 VOL 147 ISS 14
FILE LAST UPDATED: 20 Sep 2007 (20070920/ED)

=> s l3 full
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:43156 CAPLUS
DOCUMENT NUMBER: 144:163527
TITLE: The novel imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase
AUTHOR(S): Strub, Andreas; Ulrich, Wolf-Ruediger; Hesslinger, Christian; Eltze, Manfrid; Fuchss, Thomas; Strassner, Jochen; Strand, Susanne; Lehner, Martin D.; Boer, Rainer
CORPORATE SOURCE: Departments of Biochemistry, Chemistry and Pharmacology, ALTANA Pharma AG, Konstanz, Germany
SOURCE: Molecular Pharmacology (2006), 69(1), 328-337
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have identified imidazopyridine derivs. as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, resp. Inhibition of inducible NO synthase was competitive with L-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance expts., BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, resp. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher L-arginine concns. in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concns. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new

highly selective iNOS inhibitor structurally unrelated to known compds. and L-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.

IT 857379-46-5, BYK 237007
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure activity relationship studied of imidazopyridine compds. as selective inhibitors of nitric-oxide synthase isoforms)

RN 857379-46-5 CAPLUS

CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588961 CAPLUS

DOCUMENT NUMBER: 143:115536

TITLE: A preparation of (aminopyridinylethyl)imidazolopyridine derivatives, useful as inductible NO-synthase inhibitors

INVENTOR(S): Boer, Rainer; Marx, Degenhard; Ulrich, Wolf-Ruediger; Eltze, Manfrid; Nave, Ruediger; Strub, Andreas; Graedler, Ulrich; Fuchss, Thomas

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061496	A1	20050707	WO 2004-EP52373	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303515	A1	20050707	AU 2004-303515	20040930
CA 2540230	A1	20050707	CA 2004-2540230	20040930
EP 1670798	A1	20060621	EP 2004-820599	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856493	A	20061101	CN 2004-80027807	20040930
BR 2004015034	A	20061212	BR 2004-15034	20040930
JP 2007507464	T	20070329	JP 2006-530261	20040930
MX 2006PA03345	A	20060608	MX 2006-PA3345	20060324
US 2007043072	A1	20070222	US 2006-573204	20060324

NO 2006001789	A	20060424	NO 2006-1789		20060424
IN 2006MN00476	A	20070427	IN 2006-MN476		20060424
PRIORITY APPLN. INFO.:			EP 2003-22040	A	20031001
			WO 2004-EP52373	W	20040930

OTHER SOURCE(S): MARPAT 143:115536
GI



I



II

AB The invention relates to a preparation of (aminopyridinylethyl)imidazolopyridine derivs. of formula I [wherein: R1 is H or alkyl; R2 is H, halogen, NH2, (cyclo)alkyl, or CF3, etc.; R3 is H, halogen, alkyl, or alkoxyl R4 is alkyl or alkoxy], useful as antiinflammatory agents (inductible NO-synthase inhibitors). For instance, (aminopyridinylethyl)imidazolopyridine derivative II was prepared via condensation of 4-methyl-2-(tritylamino)picolinaldehyde with [3H-imidazo[4,5-b]pyridin-2-ylmethyl]triphenylphosphonium chloride and subsequent reduction of the obtained intermediate. The invention compds. were tested for NO-synthase activity [-logIC50(mol/L) values range from 6.58 to 8.15].

IT 857379-53-4P 857379-56-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)

RN 857379-53-4 CAPLUS
CN 2-Pyridinamine, 6-[2-(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-56-7 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-(6-phenyl-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]- (9CI) (CA INDEX NAME)



IT 857379-46-5P 857379-49-8P 857379-50-1P
857379-51-2P 857379-57-8P 857379-58-9P
857379-61-4P 857379-63-6P 857379-65-8P
857379-66-9P 857379-68-1P 857379-69-2P
857379-71-6P 857379-72-7P 857379-73-8P
857379-74-9P 857379-75-0P 857379-76-1P
857379-77-2P 857379-78-3P 857379-79-4P
857379-81-8P 857380-22-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)

RN 857379-46-5 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-49-8 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 857379-50-1 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 857379-46-5
CMF C14 H15 N5



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 857379-51-2 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-57-8 CAPLUS
CN Benzonitrile, 4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 857379-58-9 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-(4-methylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-61-4 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-63-6 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-65-8 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 857379-66-9 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-68-1 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 857379-69-2 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-iodophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-71-6 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-72-7 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[3-(phenylmethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-73-8 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(3,5-dichlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-74-9 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[4-(phenylmethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-75-0 CAPLUS
CN Phenol, 3-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 857379-76-1 CAPLUS
CN Pyrrolidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 857379-77-2 CAPLUS
CN Piperidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 857379-78-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 857379-79-4 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-81-8 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methoxy-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 857379-80-7
CMF C14 H15 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 857380-22-4 CAPLUS
CN Azetidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 857379-60-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)
RN 857379-60-3 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-(4-methylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:35:34 ON 21 SEP 2007)

FILE 'REGISTRY' ENTERED AT 06:36:50 ON 21 SEP 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 27 S L1 FULL

FILE 'CAPLUS' ENTERED AT 06:37:19 ON 21 SEP 2007
L4 2 S L3 FULL

=> log y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST	11.01	183.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 06:37:57 ON 21 SEP 2007